drugset / Trial / NCT00944385

Effects of Ulinastatin on Myocardial Protection and Blood Loss in Patients Undergoing Aortic Valve Replacement

NCT00944385

Phase 4 Completed Yonsei University

Summary

According to TEG (thromboelastography), as maximum amplitude is increased the amount of bleeding and transfusion and Cardiac enzyme is reduced by using ulinastatin.

Timeline

Start
2009-06
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ulinastatin Protein / enzyme biologic 30000 iu

Indications